Product PortfolioOur approach is to achieve balance in the products that we develop through a portfolio comprised of innovative vaccines and therapeutics that target infectious diseases worldwide.
Infectious Disease Products & Product Candidates
BioThrax® (Anthrax Vaccine Adsorbed)
Anthrivig™ (Human Anthrax Immunoglobulin)
PreviThrax™ (Recombinant Protective Antigen Anthrax Vaccine, Purified)
Thravixa™ (Fully Human Anthrax Monoclonal Antibody)
Tuberculosis Vaccine
Typhella™ (Typhoid Vaccine Live Oral ZH9)
H5N1 Pandemic Influenza
Oncology Product Candidates
TRU-016 (Anti-CD37)
Autoimmunity Product Candidates
SBI-087 for the Treatment of Rheumatoid Arthritis (Anti-CD20)
SBI-087 for the Treatment of Systemic Lupus Erythematosus (Anti-CD20)
To view information about Emergent product development, please refer to the Company’s Form 10-K.
ALL INVESTIGATIONAL PRODUCTS MUST SUCCESSFULLY COMPLETE THEIR RESPECTIVE DEVELOPMENT PROGRAMS AND BE APPROVED BY THE FDA (AND/OR FOREIGN EQUIVALENTS) BEFORE THEY MAY BE MARKETED.
|
